| Prospective, randomized trial on intensive SMBG management added value in non-insulin-treated T2DM patients (PRISMA): a study to determine the effect of a structured SMBG intervention. | |
| | |
MedLine Citation:
|
PMID: 22189755 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Self-monitoring of blood glucose (SMBG) is a core component of diabetes management. However, the International Diabetes Federation recommends that SMBG be performed in a structured manner and that the data are accurately interpreted and used to take appropriate therapeutic actions. We designed a study to evaluate the impact of structured SMBG on glycemic control in non-insulin-treated type 2 diabetes (T2DM) patients. The Prospective, Randomized Trial on Intensive SMBG Management Added Value in Non-insulin-Treated T2DM Patients (PRISMA) is a 12-month, prospective, multicenter, open, parallel group, randomized, and controlled trial to evaluate the added value of an intensive, structured SMBG regimen in T2DM patients treated with oral agents and/or diet. One thousand patients (500 per arm) will be enrolled at 39 clinical sites in Italy. Eligible patients will be randomized to the intensive structured monitoring (ISM) group or the active control (AC) group, with a glycosylated hemoglobin (HbA1c) target of <7.0%. Intervention will comprise (1) structured SMBG (4-point daily glucose profiles on 3 days per week [ISM]; discretionary, unstructured SMBG [AC]); (2) comprehensive patient education (both groups); and (3) clinician's adjustment of diabetes medications using an algorithm targeting SMBG levels, HbA1c and hypoglycemia (ISM) or HbA1c and hypoglycemia (AC). The intervention and trial design build upon previous research by emphasizing appropriate and collaborative use of SMBG by both patients and physicians. Utilization of per protocol and intent-to-treat analyses facilitates assessment of the intervention. Inclusion of multiple dependent variables allows us to assess the broader impact of the intervention, including changes in patient and physician attitudes and behaviors. ClinicalTrials.gov (NCT00643474). |
| | |
Authors:
|
Marina Scavini; Emanuele Bosi; Antonio Ceriello; Francesco Giorgino; Massimo Porta; Antonio Tiengo; Giacomo Vespasiani; Davide Bottalico; Raffaele Marino; Christopher Parkin; Erminio Bonizzoni; Domenico Cucinotta |
Related Documents
:
|
9052055 - Use of continuous subcutaneous insulin infusion in young adolescents with diabetes mell... 4041955 - Blood glucose control by an artificial endocrine pancreas in a patient with phaeochromo... 665775 - Action of phlorizin on luminal and antiluminal membranes of proximal cells of kidney. 6371625 - Use of intravenous fluids before cesarean section: effects on perinatal glucose, insuli... 21059515 - Third nerve palsy: analysis of 1400 personally-examined inpatients. 12960065 - Mastoparan-induced insulin secretion from insulin-secreting betatc3 and ins-1 cells: ev... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-22 |
Journal Detail:
|
Title: Acta diabetologica Volume: - ISSN: 1432-5233 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-22 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9200299 Medline TA: Acta Diabetol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Diabetes Research Institute, San Raffaele Scientific Institute, Milan, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Electrochemical methods - important means for fabrication of fluorescent nanoparticles.
Next Document: High leukocyte count and interleukin-10 predict high on-treatment-platelet-reactivity in patients tr...